Table 3.
Comparison of Visual and Anatomic Outcomes in Patients Treated with 0.5 mg versus 2.0 mg Ranibizumab
| Outcome | Branch Retinal Vein Occlusion |
Central Retinal Vein Occlusion |
||||
|---|---|---|---|---|---|---|
|
0.5 mg RBZ (n = 22) |
2.0 mg RBZ (n = 20) |
P Value |
0.5 mg RBZ (n = 19) |
2.0 mg RBZ (n = 20) |
P Value | |
| BCVA at baseline (letter score) | 54.3±3.2 | 48.9±3.6 | 0.27 | 47.1±3.7 | 46.7±3.0 | 0.78 |
| BCVA at 24 wks (letter score) | 66.4±3.4 | 63.4±2.7 | 0.49 | 62.6±4.2 | 62.5±3.5 | 0.97 |
| Change from baseline BCVA | 12.1±2.9 | 14.6±2.3 | 0.31 | 15.5±2.4 | 15.8±2.4 | 0.94 |
| Percentage of patients gaining in letter score (no. of letters) | ||||||
| ≥15 | 27.3 | 50.0 | 0.23 | 52.6 | 60.0 | 0.89 |
| ≥10 | 54.5 | 70.0 | 0.48 | 84.2 | 75.0 | 0.70 |
| ≥5 | 63.6 | 90.0 | 0.07 | 84.2 | 85.0 | 1.0 |
| CST at baseline (μm) | 539.2±36.5 | 624.0±46.1 | 0.16 | 608.6±40.1 | 672.8±46.5 | 0.33 |
| CST at 24 wks (μm) | 336.0±29.1 | 331.9±20.0 | 0.67 | 355.1±34.4 | 276.7±12.4 | 0.14 |
| Change from baseline CST | −203.3±41.0 | −292.1±51.7 | 0.19 | −253.5±43.0 | −396.1±48.1 | 0.03 |
| Percentage (no.) of patients with CST ≤320 μm at 24 wks | 68.2 (15) | 55.0 (11) | 0.58 | 52.6 (10) | 90.0 (18) | 0.03 |
BCVA = best-corrected visual acuity; CST = central subfield thickness; RBZ = Ranibizumab.